2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses

Dose selection is a Domain I study-design skill on the DABT exam: the high dose must be high enough to stress the biology and low enough that animals survive in interpretable condition. Independent OpenExamPrep material in this section treats range-finding, MTD versus MFD versus limit dose, geometric spacing, satellite toxicokinetics, and recovery as one connected protocol decision. A high dose that is too timid cannot support a NOAEL, LOAEL, or BMD. A high dose that is too brutal produces deaths, cachexia, or diet refusal, and then organ weights, clinical pathology, and tumors no longer mean what the sponsor hoped they would mean.

Range-finding and dose-range-finding (DRF)

Almost no GLP chronic or carcinogenicity high dose is invented on protocol-signature day. Laboratories walk a ladder so that the definitive study inherits an empirically tolerated top dose.

ICH S1C(R2) expects the MTD for a 2-year rodent carcinogenicity study to be estimated from a 90-day dose-ranging study in mice or a longer-term ranging study in rats, not from an LD50 fraction. If the 90-day high dose already kills animals or drops body-weight gain far past about 10%, that dose is not a 24-month MTD candidate—toxicity generally accumulates with time, it does not melt away.

Range-finding is also where palatability, precipitation in vehicle, and local irritation declare themselves. A chemical tolerated at 1000 mg/kg/day by gavage in a 14-day study may be refused in diet at the same milligram-per-kilogram intake because of taste or odor. The DRF route, vehicle, and dosing regimen should match the definitive study, or the MTD will not transfer.

MTD, MFD, and limit dose are not interchangeable

Maximum tolerated dose (MTD). In chronic and carcinogenicity practice the MTD is the highest dose that produces some toxicity over the full study duration without causing death, severe suffering, or physiologic disruption that would invalidate the study (examples used in ICH S1C(R2) include profound hypotension or inhibition of clotting with spontaneous bleeding). OECD Guidance Document 116, which TG 451 (carcinogenicity), 452 (chronic toxicity), and 453 (combined chronic/carcinogenicity) point to for dose selection, and ICH S1C(R2) both treat a modest body-weight effect—classically on the order of a 10% decrement in body-weight gain versus concurrent controls—plus target-organ or clinical-pathology findings as evidence the high dose was high enough. Pushing well beyond a 10% body-weight loss, especially with mortality, is not “more conservative.” It is a wasting study wearing a carcinogenicity protocol.

Maximum feasible dose (MFD). Used when toxicity and pharmacokinetics will not cap the dose. ICH S1C(R2) currently treats about 5% of diet as the dietary MFD. For gavage, dermal, or inhalation, feasibility is volume, local tolerance, and physical chemistry (maximum suspendable concentration, dustiness, viscosity). MFD proves you could deliver the dose, not that you achieved an MTD.

OECD oral repeated-dose limit (1000 mg/kg/day). For OECD TG 407, 408, and the chronic-phase language in TG 452/453, if a test at 1000 mg/kg body weight/day is not expected to produce adverse effects (preliminary studies plus structural analogues), a full three-dose study may not be necessary. That ceiling applies unless human exposure indicates a higher dose must be used. This is the industrial-chemical and pesticide repeated-dose convention. It is not automatically the pharmaceutical carcinogenicity cap.

ICH S1C(R2) carcinogenicity limit (1500 mg/kg/day). For many pharmaceuticals the high dose may be capped at 1500 mg/kg/day when the maximum recommended human dose (MRHD) does not exceed 500 mg/day, provided rodent systemic exposure at 1500 mg/kg/day is at least about 10-fold (an order of magnitude) the human therapeutic exposure. If that 10-fold margin cannot be shown, the guideline expects efforts to increase rodent exposure or to reconsider the model. If the human dose exceeds 500 mg/day, the high dose may be increased toward the MFD. The 1500 mg/kg/day figure was chosen after review of FDA carcinogenicity files; a 1000 mg/kg/day pharmaceutical cap would have missed some carcinogens that appeared only at or above 1000 mg/kg.

A frequent mix-up is to recite “1.5× AUC” as the ICH S1C pharmacokinetic rule. The pragmatic PK endpoint written into S1C(R2) is about 25:1, not 1.5:1. Other ICH documents use other exposure multiples for other questions (ICH M3(R2) discusses high-dose selection for general repeated-dose toxicity, including a 1000 mg/kg/day limit or a large clinical-exposure multiple in specified situations). Do not import those numbers into a carcinogenicity high-dose item and call them S1C. S1C(R2) also allows saturation of absorption and a dose-limiting pharmacodynamic effect as high-dose justifications when further milligram escalation would not raise systemic exposure or would wreck physiology.

Geometric spacing

OECD TG 408 states that two- to four-fold intervals are frequently used for descending dose levels, and that adding a fourth treated group is often preferable to very large intervals (about 6- to 10-fold or more). The scientific goal is to land at least one dose in a no-observed-adverse-effect region and to describe slope for later BMD work.

Worked spacing contrast: 0 / 40 / 120 / 360 mg/kg/day (3× steps) can support a NOAEL and a clear high-dose effect. 0 / 10 / 100 / 1000 mg/kg/day (10× steps) may leap over the true LOAEL, leaving a NOAEL ten-fold below the first toxic dose and a poorly estimated benchmark dose. Males and females need not share identical milligram-per-kilogram doses if DRF or TK differ by sex, but that split should be written into the protocol, not invented at necropsy.

Gavage volume is part of feasibility: many repeated-dose oral designs use about 5 mL/kg for oil vehicles and about 10 mL/kg for aqueous vehicles. OECD genotoxicity TGs (for example TG 474) generally keep non-aqueous volumes at or below 1 mL/100 g (10 mL/kg), with larger aqueous volumes requiring justification. Raising milligrams by pouring a larger corn-oil bolus is how you buy vehicle toxicity rather than test-article toxicity.

Satellite TK groups, recovery, and sentinels

Rodent blood volume is small. ICH S3A and ordinary CRO practice add satellite TK animals so the main-study cohort is not serially bled (stress, anemia, missed histopathology). TK satellites are usually not the animals that define the histopathology NOAEL. Dogs and nonhuman primates can often be bled on the main study.

Recovery (reversibility) satellites answer a different question: does the effect persist after dosing stops? OECD TG 408 recommends considering at least 10 extra animals (5 per sex) in control and high-dose groups for a treatment-free period sized to the findings (commonly about 14 days after a 28-day study and about 28 days after a 90-day study). Hypertrophy that reverses without necrosis may support an adaptive reading; persistent necrosis or fibrosis does not.

Do not conflate three extra populations: TK satellites (exposure), recovery satellites (reversibility), and sentinels (OECD 451 may include about 5/sex to monitor infectious disease during a 2-year study).

Protocol scenario

A sponsor asks a CRO for an OECD 408 90-day oral gavage rat study on a bitter industrial intermediate. The 14-day DRF at 2000 mg/kg/day produced 18% body-weight loss, hunched posture, and three male deaths by day 12. 1000 mg/kg/day produced about a 7% decrement in body-weight gain, mild hepatocellular hypertrophy, and no deaths. 300 mg/kg/day was indistinguishable from vehicle. Occupational human exposure is estimated well below 1 mg/kg/day. The defensible high dose sits in the MTD region already shown at 1000 mg/kg/day, with mid and low doses geometrically spaced (for example 1000 / 300 / 100). Pushing 2000 mg/kg/day into the 90-day “to be conservative” would likely recreate mortality and invalidate organ-weight and clinical-pathology interpretation. A 1000 mg/kg/day limit test (single treated group) is not available here: the DRF already showed adverse effects at 1000. Add TK satellites if systemic exposure must be documented; add recovery animals on control and 1000 mg/kg/day if hypertrophy versus injury will matter for classification.

Traps that invalidate the study

Choosing a high dose that produces excessive mortality leaves too few animals at risk late in a carcinogenicity study. OECD TG 451 additionally says termination should be considered when survivors in the lower dose groups or the concurrent control fall below 25%—that rule protects interpretability when background disease or an overly long duration destroys the control arm, and it is not a license to kill the high-dose group. Poor palatability in diet studies mimics toxicity through caloric restriction. Using an acute LD50 fraction as the 2-year high dose without a 90-day MTD is guesswork. Treating the OECD 1000 mg/kg/day repeated-dose limit and the ICH 1500 mg/kg/day carcinogenicity limit as the same number is a classification error. Skipping concurrent controls because a limit dose “should be negative” is not a design.